Edgar Filing: QUIDEL CORP /DE/ - Form 8-K

QUIDEL CORP /DE/ Form 8-K January 06, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 6, 2017

#### **OUIDEL CORPORATION**

(Exact name of Registrant as specified in its Charter)

Delaware (State or Other Jurisdiction 0-10961 (Commission 94-2573850 (IRS Employer

of Incorporation) File Number) Identification No.)

12544 High Bluff Drive, Suite 200

San Diego, California

92130 (Zip Code)

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (858) 552-1100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: QUIDEL CORP /DE/ - Form 8-K

#### Item 2.02 Results of Operations and Financial Condition

In connection with Quidel Corporation's participation at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2017, the company is providing preliminary unaudited revenue results for its fourth quarter of 2016. Based on preliminary financial information, Quidel expects revenues in the fourth quarter of 2016 to be between \$52 million and \$53 million.

These preliminary results are based on management's initial analysis of operations for the quarter ended December 31, 2016. The company expects to issue full financial results for the fourth quarter and fiscal year 2016 in February.

The Company issued a press release announcing its preliminary revenue results for the quarter ended December 31, 2016 on January 6, 2017. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K.

Forward Looking Statements: The financial information set forth in this Form 8-K reflects the company's current preliminary revenue estimates, is subject to the completion of its audit process, and is subject to change. The company's full fourth quarter and year 2016 results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

#### Item 7.01 Regulation FD Disclosure

As referenced above, in connection with the company's participation at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017, the company is reporting Sofia instrument placements of approximately 17,500 placements at customer sites as of January 6, 2017.

Item 9.01 Financial Statements and Exhibits.

### (d) Exhibits.

The following exhibit is furnished with this current report on Form 8-K:

Exhibit Number Description of Exhibit

Press release, 99.1 dated January 6, 2017

# Edgar Filing: QUIDEL CORP /DE/ - Form 8-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 6, 2017

# QUIDEL CORPORATION

By: /s/ Randall Steward Name: Randall J. Steward Its: Chief Financial Officer